Pancreatic cholera
diseaseOn this page
Also known as islet cell WDHA syndromepancreatic WDHA syndromeVerner Morrison syndromewatery diarrhea syndromewatery diarrhea with hypokalemic alkalosiswatery diarrhea, hypokalemia, and achlorhydria syndromewatery diarrhoea syndromewatery diarrhoea with hypokalemic alkalosisWDHA syndromeWDHH
Summary
Pancreatic cholera (MONDO:0004058) is a disease and 3 clinical trials. Top therapeutic interventions include gefitinib, sorafenib, and edodekin alfa. A subtype of endocrine pancreas disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | pancreatic cholera |
| Mondo ID | MONDO:0004058 |
| DOID | DOID:6977 |
| NCIT | C3488 |
| SNOMED CT | 39998009 |
| UMLS | C0086768 |
| MedGen | 39692 |
| Is cancer (heuristic) | no |
Also known as: islet cell WDHA syndrome · pancreatic WDHA syndrome · Verner Morrison syndrome · watery diarrhea syndrome · watery diarrhea with hypokalemic alkalosis · watery diarrhea, hypokalemia, and achlorhydria syndrome · watery diarrhoea syndrome · watery diarrhoea with hypokalemic alkalosis · WDHA syndrome · WDHH
Disease family
This is a subtype of endocrine pancreas disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › pancreas disorder › endocrine pancreas disorder › pancreatic cholera
Related subtypes (11): gastrin secretion abnormality, abnormality of glucagon secretion, hyperinsulinism, post-surgical hypoinsulinemia, diabetes mellitus, aggressive insulitis, benign insulitis, pancreatic neuroendocrine neoplasm, islet cell adenomatosis, insulin-resistance syndrome type A, insulin-resistance syndrome type B
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00075439 | PHASE2 | COMPLETED | Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
| NCT00131911 | PHASE2 | COMPLETED | Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors |
| NCT00004074 | PHASE1 | COMPLETED | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| GEFITINIB | 4 | 1 |
| SORAFENIB | 4 | 1 |
| EDODEKIN ALFA | 2 | 1 |